Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens

Disease Markers

Volumn 34, Issue 3, 2013, Pages 171-177

  Buxhofer Ausch, Veronika ^a,b   Ausch, Christoph ^b,c   Zeillinger, Robert ^b   Oberkanins, Christian ^d   Dandachi, Nadia ^e   Reiner Concin, Angelika ^c   Kriegshäuser, Gernot ^b,d  

^a Second Department of Medicine   (Austria)

^b Ludwig Boltzmann Society   (Austria)

^c Department of Surgery ^*  (Austria)

^d VIENNALAB DIAGNOSTICS GMBH   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

BRAF; high resolution melting; KRAS; mutation detection; reverse hybridization

Indexed keywords

B RAF KINASE; FORMALDEHYDE; GENOMIC DNA; K RAS PROTEIN; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER TISSUE; CLINICAL PROTOCOL; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DILUTION; DNA EXTRACTION; DNA HYBRIDIZATION; EVALUATION RESEARCH; GENE MUTATION; GENE SEQUENCE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MUTANT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TEST STRIP; TUMOR CELL LINE; WILD TYPE;

EID: 84874348313     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-120960     Document Type: Article

References (39)

1. C.J. Allegra, J.M. Jessup, M.R. Somerfield et al., American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27 (2009), 2091-2096.
2. A. Bardelli and S. Siena, Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. Clin Oncol 28 (2010), 1254-1261.
3. H. Davies, G.R. Bignell, C. Cox et al.,Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949-954.
4. D. Handkiewicz-Junak, A. Czarniecka and B. Jarza̧b, Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol 322 (2010), 8-28.
5. S. Velho, C. Moutinho, L. Cirnes et al., BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 8 (2008), 255.
6. J. Dong, R.G. Phelps, R. Qiao et al., BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63 (2003), 3883-3885.
7. N. Dhomen and R. Marais, New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17 (2007), 31-39.
8. E. Domingo, E. Esṕn, M. Armengol et al., Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 39 (2004), 138-142.
9. D.J. Weisenberger, K.D. Siegmund, M. Campan et al., CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38 (2006), 787-793.
10. F. Di Nicolantonio, M. Martini, F. Molinari et al., Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26 (2008), 5705-5712.
11. H. Rajagopalan, A. Bardelli, C. Lengauer et al., Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 (2002), 934.
12. C.Wellbrock and A. Hurlstone, BRAF as therapeutic target in melanoma. Biochem Pharmacol 80 (2010), 561-567.
13. C. Ausch, V. Buxhofer-Ausch, C. Oberkanins et al., Sensitive detection of KRAS mutations in archived formalinfixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn 11 (2009), 508-513.
14. G. Kriegsḧauser, V. Auner, E. Schuster et al., KRAS mutation analysis in genomic DNA isolated from formalin-fixed paraffin-embedded ovarian tissue: evaluation of a strip-based reverse-hybridization assay. J Clin Pathol 64 (2011), 252-256.
15. A. Fariña Sarasqueta, E.Moerland, H. de Bruyne et al., SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. J Mol Diagn 13 (2011), 199-205.
16. M. Pichler, M. Balic, E Stadelmeyer et al., Evaluation of highresolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn 11 (2009),140-147.
17. L. Prix, P. Uciechowski, B. B̈ockmann et al., Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool. Clin Chem 48 (2002), 428-435.
18. C.C. Pritchard and W.M. Grady, Colorectal Cancer Molecular BiologyMoves Into Clinical Practice. Gut 60 (2011), 116-129.
19. Y. Yarden and M.X. Sliwkowski, Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001), 127-137.
20. M. Scaltriti and J. Baselga, The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12 (2006), 5268-5272.
21. S. Siena, A. Sartore-Bianci, F. Di Nicolantonio et al., A Biomarkers PredictingClinicalOutcome of EpidermalGrowth Factor-Targeted Therapyin Metastatic Colorectal Cancer. J Natl Cancer Inst 101 (2009), 1308-1324.
22. N. Nakayama, K. Nakayama, S. Yeasmin et al., KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer 99 (2008), 2020-2028.
23. G. Singer, R. Oldt 3rd, Y. Cohen et al., Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95 (2003), 484-486.
24. S. Murala, V. Alli, D. Kreisel et al., Current status of immunotherapy for the treatment of lung cancer. J Thorac Dis 2 (2010), 237-244.
25. Shepherd C, Puzanov I, Sosman JA. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep 12 (2010), 146-152.
26. D.W. Ball, Selectively targeting mutant BRAF in thyroid cancer. J Clin Endocrinol Metab 95 (2010), 60-61.
27. I.S. Boughdady, A.R. Kinsella, N.Y. Haboubi et al., K-ras genemutations in adenomas and carcinomas of the colon. Surg Oncol 1 (1992), 275-282.
28. A. Russo, V. Bazan, V. Agnese et al., Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 16 (2005), Suppl 4: iv44-49.
29. J.R. Jass, Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50 (2007), 113-130.
30. A. Marchetti, M. Milella, L. Felicioni et al., Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 11 (2009), 1084-1092.
31. J.E. Hardingham, D. Kotasek, B. Farmer et al., Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res 53 (1993), 3455-3458.
32. M. Behn, C. Thiede, A. Neuberger et al., Facilitated detection of oncogene mutations from exfoliated tissue material by a PNA-mediated 'enriched PCR' protocol. J Pathol 190 (2000), 69-75.
33. S.L. Lilleberg, J. Durocher, C. Sanders et al., High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations inAPC,TP53,K-RAS, andBRAF geneswith a novel DHPLC fluorescence detection platform. Ann N Y Acad Sci 1022 (2004), 250-256.
34. R.G. Amado, M. Wolf, M. Peeters et al., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008), 1626-1634.
35. W. Laosinchai-Wolf, F. Ye, V. Tran et al., Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffinembedded tissue specimens. J Clin Pathol 64 (2011), 30-36.
36. J. Tol, J.R. Dijkstra, M.E. Vink-Borger et al., High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 14 (2010), 2122-2131.
37. M. Krypuy, G.M. Newnham, D.M. Thomas et al., High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 6 (2006), 295.
38. E.S. Ma, C.L.Wong, F.B. Lawet al.,Detection ofKRASmutations in colorectal cancer by high-resolution melting analysis. J Clin Pathol 62 (2009), 886-891.
39. G.H. Reed, J.O. Kent and C.T.Wittwer, High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 8 (2007), 597-608.